+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P10151(AK9 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The AK9 antibody is associated with research targeting the AKAP9 (A-Kinase Anchoring Protein 9) protein, a scaffold protein involved in organizing signaling complexes within cells. AKAP9 anchors protein kinase A (PKA) and other enzymes to specific subcellular locations, regulating processes like cell cycle progression, cytoskeletal organization, and signal transduction. Dysregulation of AKAP9 has been linked to cancers (e.g., breast, lung, thyroid), neurological disorders, and ciliopathies.

AK9 antibodies are primarily used as research tools to study AKAP9's role in disease mechanisms. For example, they help detect AKAP9 expression levels in tissues or assess its interaction with binding partners, such as PDE4D or β-catenin, in pathways like Wnt signaling. In cancer studies, AKAP9 overexpression correlates with tumor growth and metastasis, making it a potential biomarker or therapeutic target. However, therapeutic applications of AK9 antibodies remain exploratory, with challenges in specificity and delivery. Current studies focus on elucidating AKAP9's structural domains and validating its functional roles using antibody-based assays (e.g., Western blot, immunofluorescence). Further research is needed to translate these findings into clinical interventions.